Innophos Holdings Inc. (IPHS), 259 Prospect Plains Road, Building G, Box 8000, Cranbury 08512. 609-495-2495. Randy Gress, CEO.

Innophos, a manufacturer of ingredients for industry, health food, and dietary supplements, has acquired Vermont-based NutraGenesis, a maker of “nutraceutical” ingredients that are marketed as providing health benefits, in a $28 million deal.

“The addition of NutraGenesis’ innovative, science-backed branded ingredients to our food, health and nutrition portfolio more closely aligns Innophos with consumer megatrends such as health and wellness, energized aging and clean labels,” said Innophos CEO Kim Ann Mink. “This transaction builds on the recent acquisition of Novel Ingredients, and further strengthens our position as a leading specialty ingredient solutions provider to attractive end-markets. In addition, NutraGenesis’ asset-lite business model, complementary capabilities and established presence in high-growth nutraceutical markets make this a high-value addition for Innophos.”

NutraGenesis makes products like “capros superfruit antioxidant,” saying on its website that “Indian Gooseberry is a superfruit that is widely known in Asia and has been revered for 5,000 years in Ayurvedic medicine for its health-promoting properties” and that the ingredient has anti-aging effects.

#b#FDA News#/b#

Certara, 103 Carnegie Center, Suite 300, Princeton 08540. 888-708-7444. Edmundo Muniz, chief executive officer.

The FDA has greatly expanded its use of a safety simulator program made by Certara, a drug development consulting company based in Carnegie Center. Certara says the FDA has tripled its use of the PBPK Simcyp Population-based Simulator and its Pediatric and Cardiac Safety Simulators, bringing it up to 60 licenses.

The FDA has used Simcyp since 2003. The software, which is used by 36 large biopharmaceutical companies, plus regulators and researchers around the world, models the effect of drugs in simulated patient populations.

Stephen Toon, president and managing director of Certara’s Simcyp division, said using the program ultimately makes drugs safer, faster, and cheaper to develop, and that the computer simulation can answer “what if” questions about drugs being developed. “Certara’s primary goals are to improve the efficiency of the drug development process and help get safer, more effective medications to patients who need them. We are partnering with the FDA and other global regulatory agencies to achieve those shared goals,” he said.

Certara says the FDA’s Center for Drug Evaluation and Research is currently using the software to predict clinical outcomes, inform clinical trial designs, support evidence of effectiveness, optimize dosing, predict product safety, and evaluate potential adverse event mechanisms.

The FDA also is funding Certara to conduct a research project with the University of Leuven in Belgium that will allow Simcyp to simulate drugs’ effects on the gastrointestinal tract. The agency also gave Certara a grant to enable the software to model drugs that are applied to the skin, such as creams and gels. The FDA is also funding a third project that will extend Sim­cyp to dogs.


Keith Roughgarden, 54, on November 16. He was a forklift operator with the Hibbert Group of Trenton.

Dr. Jay Brandinger, 90, on October 25. A vice president at RCA before retiring in 1991, he later taught at Rider and was executive director of the New Jersey Commission on Science and Technology.

Charles J. DeAngelo Jr., 84, on November 11. He was section chief for water resources at the NJ Department of Environmental Protection.

Alan Dutko, 70, on November 12. He worked for AT&T and Lucent Technologies.

Diosdado Gonzales, 62, on November 8. He was a computer programmer for Convatec Software Consulting in Skillman.

Peter Soltis Jr., 79, on November 13. He was president of the J. Allen Hooper Funeral Chapel in Morrisville.

Facebook Comments